StockBlog

VIR : hold on and be patient

NASDAQ:VIR   Vir Biotechnology, Inc.
After the very good results of the first quarter,the stock reacted well. The hepatitis cases remain under control. The company's balance sheet is clean and this gives hope for the future...

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。